New Data from Hypertension Program Presented at the European Society of Cardiology Congress 2025, Madrid

30 Aug, 2025 New Data from Hypertension Program Presented at the European Society of Cardiology Congress 2025, Madrid

Presentations demonstrated the potential of RNAi therapeutics to transform the treatment of cardiovascular disease.

Pagidipati, et. al “KARDIA-3: Zilebesiran as Add-on Therapy in Adults With Hypertension Who Have Established Cardiovascular Disease or Are at High Cardiovascular Risk”

Highlights include data from Cohort A of the KARDIA-3 Phase 2 study evaluating the investigational RNAi therapeutic, zilebesiran, in patients with uncontrolled hypertension and high cardiovascular risk. The data presented as a late-breaking abstract underscore the promise of zilebesiran in addressing unmet needs in hypertension and cardiovascular risk, and support the initiation of a Phase 3 cardiovascular outcomes trial.